D2G Oncology utilizes genomic profiling to match cancer therapies with specific genotypes, enhancing the precision of treatment plans for patients. This approach addresses the challenge of ineffective therapies by ensuring that patients receive medications tailored to their unique genetic makeup.
Funding
$8.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients receive treatments that are ultimately ineffective due to the unique genetic characteristics of their tumors. This trial-and-error approach can lead to delayed treatment, disease progression, and unnecessary side effects. Selecting the most appropriate therapy based on a patient's individual genomic profile remains a significant challenge in oncology.
Solution
D2G Oncology offers genomic profiling services to personalize cancer treatment plans. By analyzing the specific genetic makeup of a patient's tumor, D2G Oncology identifies the therapies most likely to be effective. This precision medicine approach aims to improve patient outcomes by ensuring they receive treatments tailored to their unique genomic profile, potentially avoiding ineffective therapies and minimizing adverse effects. The company's services help oncologists make informed decisions about treatment options based on comprehensive genomic data.
Target Audience
D2G Oncology's primary customers are oncologists and other healthcare professionals involved in cancer treatment, as well as cancer patients seeking personalized treatment options.
Features
- Genomic profiling of tumor samples to identify actionable mutations and biomarkers
- Comprehensive analysis of genetic data to predict drug response
- Personalized treatment recommendations based on individual patient profiles